Navigation Links
VIVUS to Present at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference.  

The VIVUS presentation will take place at the Palace Hotel in New York, New York on Tuesday, April 5, 2011 at 2:00 p.m. ET.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com. CONTACT:   VIVUS, Inc.Investor Relations: The Trout GroupTimothy E. Morris

Brian KorbChief Financial Officer

bkorb@troutgroup.com650-934-5200

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
2. VIVUS to Present at Four Upcoming Investor Conferences
3. VIVUS to Present at Two Upcoming Investor Conferences
4. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
5. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
6. VIVUS to Present at Four Upcoming Healthcare Conferences
7. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
8. VIVUS to Present at the Needham and Company Life Sciences Conference
9. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
10. VIVUS Reports First Quarter 2009 Financial Results and Highlights
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Million to $247 Million -, Third Quarter 2008 Highlights:, -- ... 2007 -- Total revenues without Osteocel of $62.5 million; up 62.3% ... -- Gross profit of $54.7 million; up 73.2% from the third quarter ... in the third quarter of 2007, -- GAAP loss per ...
... Alert Limited,(OTC Bulletin Board: DYMC) (the "Company") is ... medical cannabis-based,pharmaceutical products. Today the Company is pleased ... all of the assets of Cannex, a privately,owned ... political,activist Steven W. Kubby (http://www.kubby.com ). The ...
... At CHEST 2008, PARI,Respiratory Equipment will ... breath-enhanced nebulizers and their in-vitro,performance and delivery ... "Our goal in testing various breath-enhanced ... delivery rate to ensure patients,receive clinically effective ...
Cached Biology Technology:Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... Stem Cells and Cancer Research Group headed by Dr ... Oncology (VHIO) has identified the molecular mechanisms that determine ... for colon cancer treatment. The study led by VHIO ... laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, ...
... atmosphere through summer thunderstorm clouds, according to a computational ... . How much the warming effect of these clouds ... yet clear. To find out, researchers need to incorporate ... Pollution strengthens thunderstorm clouds, causing their anvil-shaped tops to ...
... Cell cultures need glucose for energy, but ... in which cell proteins undergo unwanted structural changes. ... and time-consuming handling of the cell culture. A ... Singapore and Singapore,s Institute of Microelectronics is developing ...
Cached Biology News:Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Pollution teams with thunderclouds to warm atmosphere 2Pollution teams with thunderclouds to warm atmosphere 3
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
...
... Mynox is the first ... by killing them, and not ... is the only anti-mycoplasma agent ... clean virus stocks directly. The ...
Biology Products: